Effect of CCR2-V64I on the Susceptibility of Patients to Cancer

Abstract

Background. Results from the studies investigating the impact of CC chemokine receptor 2 (CCR2) polymorphism on the risk of cancers are diverse. An updated meta-analysis was conducted to access the relationship between cancer risk and CCR2-V64I polymorphism. Methods. We performed a meta-analysis using STATA 11.0 based on a comprehensive retrieval in WanFang Data, PubMed, China National Knowledge Infrastructure, EMBASE, and Web of Science databases up to January 20, 2023. Results. We included 23 studies in our analysis. Overall, we found CCR2-V64I polymorphism was remarkably related to cancer risk (OR = 1.39, 95% CI = 1.14–1.70, and $P=0.001$ for A vs G; OR = 1.87, 95% CI = 1.30–2.70, and $P=0.001$ for AA vs GG; OR = 1.35, 95% CI = 1.03–1.78, and $P=0.032$ for GA vs GG; OR = 1.45, 95% CI = 1.11–1.90, and $P=0.006$ for AA + GA vs GG; OR = 1.69, 95% CI = 1.20–2.37, and $P=0.003$ for AA vs GA + GG). In the ethnicity subgroup analysis, the relevancy between CCR2-V64I polymorphism and an increased cancer risk was discovered among Asians (OR = 1.57, 95% CI = 1.30–1.91, and $P<0.001$ for A vs G; OR = 2.30, 95% CI = 1.64–3.24, and $P<0.001$ for AA vs GG; OR = 1.35, 95% CI = 1.10–1.67, and $P=0.005$ for GA vs GG; OR = 1.52, 95% CI = 1.25–1.87, and $P<0.001$ for AA + GA vs GG; OR = 2.21, 95% CI = 1.58–3.08, and $P<0.001$ for AA vs GA + GG). In addition, the subgroup analysis in the light of cancer types demonstrated that CCR2-V64I polymorphism was strongly correlated with bladder cancer (OR = 3.04, 95% CI = 1.09–8.45, and $P=0.033$ for AA vs GG; OR = 2.84, 95% CI = 1.07–7.09, and $P=0.035$ for AA vs GA + GG) and oral cancer (OR = 1.83, 95% CI = 1.39-2.42, and $P<0.001$ for A vs G; OR = 2.04, 95% CI = 1.47–2.85, and $P<0.001$ for GA vs GG; OR = 2.03, 95% CI = 1.48–2.79, and $P<0.001$ for AA + GA vs GG). Conclusion. The meta-analysis suggested that CCR2-V64I polymorphism might be a high-risk factor for cancers among Asians, especially for bladder and oral cancers.